Neurocrine Biosciences (NBIX) Leases (2019 - 2021)
Historic Leases for Neurocrine Biosciences (NBIX) over the last 3 years, with Q3 2021 value amounting to $97.9 million.
- Neurocrine Biosciences' Leases rose 3788.73% to $97.9 million in Q3 2021 from the same period last year, while for Sep 2021 it was $97.9 million, marking a year-over-year increase of 3788.73%. This contributed to the annual value of $82.8 million for FY2020, which is 1144.01% up from last year.
- As of Q3 2021, Neurocrine Biosciences' Leases stood at $97.9 million, which was up 3788.73% from $100.3 million recorded in Q2 2021.
- In the past 5 years, Neurocrine Biosciences' Leases ranged from a high of $100.3 million in Q2 2021 and a low of $49.1 million during Q2 2019
- Over the past 3 years, Neurocrine Biosciences' median Leases value was $73.3 million (recorded in 2020), while the average stood at $75.4 million.
- Over the last 5 years, Neurocrine Biosciences' Leases had its largest YoY gain of 4866.95% in 2020, and its largest YoY loss of 1144.01% in 2020.
- Over the past 3 years, Neurocrine Biosciences' Leases (Quarter) stood at $74.3 million in 2019, then grew by 11.44% to $82.8 million in 2020, then increased by 18.24% to $97.9 million in 2021.
- Its Leases stands at $97.9 million for Q3 2021, versus $100.3 million for Q2 2021 and $97.0 million for Q1 2021.